Screener
Candel Therapeutics, Inc. CADL Q3 2026 earnings
Reported November 12, 2026 · After market close
EPS-$0.28Beat by $0.06
EPS estimate-$0.34
“On the clinical side, we were honored to have had three posters accepted for presentation at SITC, featuring data on aglatimagene in localized prostate cancer and non-small cell lung cancer, and linoserpaturev in recurrent high-grade glioma. Together, the new biomarker data provide mechanistic support for the systemic effect and long-term clinical outcomes observed in our phase 3 trial of aglatimagene in patients with intermediate- to high-risk localized prostate cancer.”
Next report
Date not yet announcedVersus estimates
Diluted EPS
FAQ
- When did Candel Therapeutics, Inc. report Q3 2026 earnings?
- Candel Therapeutics, Inc. (CADL) reported Q3 2026 earnings on November 12, 2026 after market close.
- What were Candel Therapeutics, Inc.'s Q3 2026 revenue and EPS?
- Candel Therapeutics, Inc. reported eps of $-0.28 for Q3 2026.
- Did Candel Therapeutics, Inc. beat estimates in Q3 2026?
- EPS beat the consensus estimate of $-0.34 by $0.06.
- How did Candel Therapeutics, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps declined 33.3% from $-0.21.
- Where can I find Candel Therapeutics, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-458316) and the 10-Q periodic report (0001193125-26-458380) directly on SEC EDGAR. The filing index links above go to sec.gov.
